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Pharmacological and immunhistological investigations of the involvement 
of striatal alterations in the glutamatergic system in a genetic animal model 
of primary paroxysmal dystonia 
 
Dystonia is one of the most common human movement disorders, characterized by 
involuntary muscle cocontractions, which cause repetitive twisting movements. At present, 
the dt
sz
-hamster represents the only established and thoroughly characterized animal model of 
the human so called primary paroxysmal non-kinesiogenic dystonic choreoathetosis (PDC), in 
which dystonic attacks can be induced by stress and last up to several hours. In PDC and other 
types of primary dystonia, pathomorphological alterations of the CNS are not detectable by 
using standard techniques. Findings in secondary dystonia point to biochemical dysfunctions 
within the basal ganglia, especially the striatum. In view of the lack of knowledge about the 
pathophysiology of this disease, rational therapeutic strategies are missing. 
The age-dependent character of primary dystonia in the dt
sz
-hamster allows comparative 
studies between animals at the age of maximum expression of dystonia (age: 30.- 42. day of 
life) and at an age after spontaneous remission of dystonic attacks (>90. day of life). Previous 
immunhistochemical studies demonstrated an ontogenetic deficit of inhibitory striatal 
GABAergic parvalbumin-immunreactive (PV
+
) interneurons, which probably represents the 
primary defect in the dt
sz
 mutant (Richter und Hamann, 2002). In order to clarify if other types 
of striatal interneurons of the dt
sz
-hamster also show an altered density, nitric oxide synthase-
immunreactive (NOS
+
) interneurons, which closely interact with the glutamatergic system, 
were examined by immunhistochemical investigations in the present study. Recent 
electrophysiological and neurochemical studies pointed to an involvement of an increased 
corticostriatal glutamatergic activity in the manifestation of dystonic attacks in the dt
sz
-
mutants. Therefore, in the present study, striatal manipulations of glutamate receptors were 
carried out. In order to clarify the role of an abnormal striatal NMDA-receptor-stimulated 
NO-release and of a deficit of NOS
+
-interneurons, as found in the present study, striatal 
applications of inhibitors of neuronal nitric oxide synthase (nNOS) were performed. 
  Summary 
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The density of the immunhistochemical marked striatal NOS
+
-interneurons at the age of 
maximum expression was significantly reduced within the whole striatum (-21%) of mutant 
hamsters in comparison to age-matched control animals. This deficit disappeared after 
spontaneous remission of dystonia. The lack of effects of striatal injections of the nNOS-
inhibitors 7-nitroindazole and N
ω
-propyl-L-arginine on the severity of dystonia indicated that 
striatal changes in nNOS are not critically involved in the pathophysiology of the PDC of the 
dt
sz
-Hamster. In contrast to the central relevance of the reduced density of striatal PV
+
-
interneurons in primary paroxysmal dystonia in the mutant hamster, the decreased density of 
striatal NOS
+
-interneurons may be an epiphenomenon, probably caused by an overall retarded 
postnatal cell migration of striatal interneurons in the dt
sz
 mutant. 
An antidystonic effect, as observed in previous studies after systemic administration of 
glutamate receptor antagonists, was only achieved by striatal microinjections of the AMPA 
receptor antagonist NBQX at the dosage of 0,08 µg per hemisphere. Combined treatment of 
0,08µg NBQX and the NMDA receptor antagonist AP-5 failed to show a potentiation of the 
antidystonic efficacy in the mutant hamster. Three other doses of 0,03 µg, 0,16 µg and 0,25 
µg per hemisphere did not produce any reduction of the severity of dystonic attacks. The lack 
of antidystonic effects at higher concentrations was possibly due to inhibition of the already 
deficient PV
+
-interneurons. None of the NMDA receptor antagonists decreased the severity of 
dystonia in the dt
sz
-hamster after single injection in the striatum. With regard to the 
antidystonic effects of glutamate receptor antagonists after systemic administration, 
demonstrated in previous studies in the dt
sz
-mutant, these results suggest an involvement of 
the glutamatergic system of other brain regions in the pathophysiology of the primary 
dystonia in the mutant hamster. 
In conclusion, these results do not support the hypothesis of an involvement of an abnormal 
activity of the striatal glutamatergic system in the manifestation of dystonic attacks in the dt
sz
-
hamster. The reduced density of striatal NOS
+
-interneurons should initiate ongoing 
examinations of other types of striatal (inter-)neurons. 
